Genomics

The International Society for Pharmaceutical Engineering has announced the 2021 Facility of the Year Awards category winners. The awards include:

Promega Corporation opened the 283,000-sf Kornberg Center in April of 2021 in Fitchburg, Wis. Designed by Ramlow/Stein and SmithGroup, the three-story facility provides advanced laboratories for core product and technology development in cellular and molecular biology, biochemistry, genetic identity, clinical diagnostics, and scientific applications.

The life sciences sector is experiencing an era of unprecedented growth driven by a surge in both public and private funding combined with a post-pandemic sense of urgency and market opportunity. According to a report released by Newmark in January 2021, more than 36 million sf of new construction is expected to be delivered in the nation’s top 14 life science markets, as life science investments more than triple. While demand for life science and biotech facilities has been growing steadily over the past decade, the COVID-19 crisis heightened national awareness around the need for increased research, diagnostic, and domestic manufacturing capabilities. Investors are also seeing significant potential in the future of personalized medicine, genomics, and other life science-related fields, as emerging technologies and research disciplines converge.

Canadian developer Oxford Properties has expanded its real estate portfolio in the United States with the acquisition of four new assets. Representing an investment of $276 million in the burgeoning life sciences industry, the purchase included a total of 415,000 sf of existing space and associated developable land. Oxford Properties plans to spend an additional $500 million to repurpose, renovate, and expand the four structures to create leading-edge lab and office environments for biomedical tenants. 

Silverstein Properties & Cantor Fitzgerald are partnering with University Place Associates to create a biomedical innovation center in Philadelphia. Providing leading-edge lab and office facilities, 3.0 University Place is pre-certified as LEED Platinum v4 BD+C for core and shell, and will also target WELL Core v2 Platinum certification.

BioMed Realty is creating a 482,000-sf life sciences hub in Boston's Seaport District. Previously serving as the corporate headquarters of John Hancock, the building was acquired by BioMed Realty in late 2020. Featuring robust mechanical and electrical systems, the existing structure has attained LEED Platinum sustainable design certification and includes a variety of collaborative meeting areas. The facility will be renovated to provide sophisticated lab and office environments for biomedical companies. Occupancy is expected in the second half of 2022. 

Thermo Fisher Scientific is expanding its global production capacity for vaccines, medicines, and biologic therapies. Construction will begin in mid-2021 on a 130,000-sf facility in Greenville, N.C. Slated for completion in 2022, the standalone structure will accommodate two live-virus filling lines. The project is part of a $500 million investment in the site that will add six new lines in existing buildings to support commercial-scale liquid vial filling and the creation of lyophilized materials. 

Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing.

Stanford University dedicated the $210 million Biomedical Innovation Building in November of 2020 in Palo Alto, Calif. Designed by ZGF Architects with Research Facilities Design (RFD) as laboratory design consultant, the 190,439-gsf facility strategically collocates investigators with expertise in cardiovascular medicine, pediatrics, orthopaedics, immunotherapy, personalized genomics, otolaryngology, and asthma and allergy.

Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas. Representing an expansion of Fujifilm's cGMP manufacturing campus, the 60,000-sf facility will feature dedicated labs for process development and innovation. Research environments with BSL-2 capabilities will integrate advanced technologies for upstream, downstream, and analytical development.

Codiak BioSciences is constructing a 12,000-sf clinical manufacturing center in Lexington, Mass. The project includes the build-out of a leased lab and office building to create a GMP facility for the production of exosome therapeutics. Codiak is incorporating G-CON Manufacturing's PODs into the center to provide flexible cleanroom capacity. The prefabricated units offer exceptional scalability and mobility, and can be easily repurposed to meet future needs.

CRISPR Therapeutics signed a full-building lease in July of 2020 for a 263,500-sf facility in Boston's Seaport district. Breakthrough Properties is the developer for the project, which was designed by Payette to provide best-in-class laboratory environments for life science research. Both LEED Gold and Fitwel certification will be sought for the structure, which will offer multiple amenities including outdoor terraces and a fitness center.

DiNAQOR AG completed construction in July of 2020 on a 9,687-sf R&D center in Schlieren, Switzerland. Located in the Bio-Technopark Schlieren-Zürich, the BSL-2 facility will enable DiNAQOR to fast-track the development of its human-induced pluripotent stem cells (iPSC) and engineered heart tissue platform. Accelerating the creation of next-generation genetic medicine methodologies, the project also provides sophisticated infrastructure to further optimize the company's proprietary locoregional heart perfusion approach.

University Hospital Hamburg-Eppendorf is planning to build a 193,000-sf translational medicine hub in Hamburg, Germany. Housing the Campus Research II facility and the Hamburg Center for Translational Immunology, the interdisciplinary complex will provide 150 labs for the study of inflammation, infection, and immunology. The structure will also accommodate collaborative workspaces, instrumentation suites, research offices, and interaction zones.

Genomic Partnership Wales is planning to construct a research facility in Cardiff in the United Kingdom to accelerate the development of pharmaceutical therapies. Created by a consortium of government, academic, and medical partners, the project involves the redevelopment of an existing two-story building to provide leading-edge genetics labs, seminar rooms, treatment suites, offices, freezer rooms, and support. The facility will include CL2 biocontainment research suites to ensure compliance with the UK's HBN 15 regulations for pathology services.